{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-032422","form_type":"8-K","ticker":"CTNM","cik":"0001855175","company_name":"Contineum Therapeutics, Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.831560+00:00","generated_at":"2026-05-17T01:24:53.800633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Contineum Therapeutics Q3 net loss $12.8M, cash $182.4M, pipeline milestones affirmed","bullets":["Cash, cash equivalents and marketable securities $182.4M; projected cash runway extended through 2028.","Net loss $12.8M vs $10.3M in prior-year quarter; R&D expenses $11.0M (+13% YoY).","Generated $19.0M from ATM offerings of 3.2M shares at weighted avg $6.04/share.","Topline data from PIPE-307 Phase 2 VISTA RRMS trial expected Q4 2025; global Phase 2 for PIPE-791 IPF to initiate Q4 2025.","Deferred initiation of PIPE-791 PrMS and CTX-343 trials to extend cash runway."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-032422","json":"https://secwatch.observer/filing/0001437749-25-032422.json","markdown":"https://secwatch.observer/filing/0001437749-25-032422.md","text":"https://secwatch.observer/filing/0001437749-25-032422.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925032422/0001437749-25-032422-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925032422/ctnm20251015_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:24:53.800633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}